Self-efficacy
hypertension
HYPERTENSION, CONCOMITANT DISEASE
At baseline, the mean (SD) self-efficacy was 59.21 (10.44) in the intervention group and 57.84 (11.71) among controls. After 12 weeks of follow-up, the mean (SD) hypertension compliance increased by 12.89 (11.95) in the intervention group and by 5.43 (10.54) in the control group (between-group difference, 7.47; 95% CI, 3.62 to 11.31; Subgroup analyses of the association of the intervention with self-efficacy by gender, age, number of concomitant diseases, years of hypertension, baseline BMI, baseline hypertension compliance and baseline SBP showed no significant between-group differences, while was significant by baseline self-efficacy (